Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV140 for prevention of recurrent urinary tract infections in adults aged 65 years or older
ACTRN12623000258651Phase 3Not yet recruiting
- Sponsor
- Australasian Medical & Scientific
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of MV140 in urinary tract infection (UTI) (2 arms), sponsored by Australasian Medical & Scientific. Primary endpoint: Number of urinary tract infections over 12 months after treatment completion. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
MV140
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ACTRN12623000258651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000258651.